This 48-week trial is the longest to date to evaluate the safety, tolerability, and efficacy across multiple clinical endpoints of IV administration of Trappsol® CycloTM (HP-β-CD) in NPC1 patients. Here, CYP4V2 is linked to Niemann-Pick disease, type C1.